Quick Facts

• Relieves symptoms of depression.
• Manages psychotic symptoms, such as delusions and hallucinations.
• Supports management of certain chronic psychoses.

---

Motival is utilized for the management of certain psychiatric conditions. The combination of its active components, nortriptyline and fluphenazine, contributes to its therapeutic profile. Nortriptyline is indicated for the relief of symptoms of depression.

Fluphenazine is classified as an antipsychotic medication, and it is used to treat chronic psychoses and manage psychotic symptoms such as hallucinations and delusions. These components work together to help improve thinking, mood, and behavior in affected individuals. In some formulations, this combination is specifically used to address depression in patients with a concurrent diagnosis of chronic psychosis.

Treatment with this medication is typically part of a comprehensive management plan. The benefits involve stabilization of mood and a reduction in the severity of psychotic symptoms.

---

Eligibility for Motival (Nortriptyline/Fluphenazine)

The patient population eligible to use the combination medicine Motival is precisely defined by regulatory authorities and includes specific restrictions based on age, existing medical conditions, and concurrent medication use.

Population Status	Regulatory Rule (Official Basis)
Approved Population	Adults (typically 18 to 60 years) for the labeled indication (e.g., mixed anxiety-depressive states).
Not Recommended	Children and adolescents under 18 years of age; the elderly population over 60 years of age.
Duration Restriction	Use should not exceed three months for the approved patient population, as specified in the labeling.

Absolute Contraindications

Motival must not be used in patients with the following conditions, as these are listed as absolute prohibitions in official labeling:

• Severe Organ Dysfunction: Severe hepatic dysfunction or severe renal dysfunction.
• Cardiovascular Conditions: Severe cardiac insufficiency or the acute recovery period following a myocardial infarction.
• Neurological Conditions: Epilepsy or suspected/established organic brain damage.
• Blood Disorders: The presence of blood dyscrasias.
• Other Medications: Patients who are currently receiving, or have received within the last two weeks, a Monoamine Oxidase Inhibitor (MAOI).
• Hypersensitivity: Known hypersensitivity to nortriptyline, fluphenazine, other phenothiazines, or any component of the formulation.

Pregnancy and Lactation

• Pregnancy: Safe use during pregnancy has not been established. Use is typically discouraged unless the potential benefit justifies the potential risk.
• Lactation: Breastfeeding is not recommended during treatment with this medicine.

Motival Interactions with other medicines and products

The official regulatory profile for Motival (Nortriptyline/Fluphenazine) establishes several Mandatory Contraindications and restrictions based on documented interaction risks.

Interaction Classification	Interacting Agents / Classes	Documented Outcome or Constraint
Strictly Prohibited	Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue.	Co-administration is forbidden due to the risk of hyperpyretic crises and fatalities.
	QT-prolonging agents and large doses of CNS Depressants.	Prohibited due to potentiation of cardiac effects or additive central nervous system depression.
Pharmacokinetic	Quinidine and CYP2D6 Inhibitors (e.g., Cimetidine, Fluoxetine).	Result in significantly lower clearance and a longer plasma half-life of the Nortriptyline component.
Pharmacodynamic	Antihypertensive Agents (e.g., Guanethidine), Anticholinergics (e.g., Atropine), Thyroid Medication.	Nortriptyline may block the antihypertensive effect; Fluphenazine has additive anticholinergic effects; Thyroid co-use risks cardiac arrhythmias.

Interaction-Related Constraints

A procedural constraint requires that MAO Inhibitors must be discontinued for at least two weeks before initiating Motival therapy. Furthermore, excessive consumption of alcohol is noted to have a potentiating effect with Nortriptyline, increasing the documented danger of overdosage. The overall structure highlights the necessity for stringent co-administration rules.

Motival is classified as a selective inhibitor of the G-Protein-Coupled Receptor Kinase 2 (GRK2) enzyme. GRK2 mediates the phosphorylation and subsequent desensitization of beta-adrenergic receptors (betaARs). By binding to the GRK2 active site, Motival reduces the enzyme's capacity to phosphorylate the receptor complex. This molecular interaction represents the primary biological target.

The specific inhibition of GRK2 modulates the intracellular signaling cascade involving the Galphaq protein and downstream effectors. Decreased phosphorylation of betaARs results in a sustained activation state and increased membrane presence of the receptor, increasing signaling efficiency in target tissues.

The modulation of receptor density and signal transduction primarily influences cardiac function. At the system level, the enhanced signaling from the non-desensitized betaARs leads to altered inotropy (contractility) and chronotropy (rate) within the myocardium. This effect constitutes the physiological modulation observed with Motival activity.

How to Use Motival — Official Administration Guidelines

Motival (nortriptyline and fluphenazine) is administered as an oral tablet. Adherence to the specific dosing and duration limits is required for correct use.

---

Administration Scope

Instruction Category	Official Guideline
Route of Administration	Oral
Standard Dosing	One tablet three times daily
Age-Group Rules	Not indicated for patients over 60 years of age or for children
Maximum Duration	Treatment should not exceed 3 months
Therapy Review Rule	If no response occurs in 4 weeks, alternative therapy must be used

---

Procedural Structure

The established protocol for the use of this fixed-dose combination medicine includes mandatory steps:

1. Start therapy by taking one tablet.
2. Take the remaining two doses throughout the day to meet the three times daily frequency.
3. Adhere to the daily dosing schedule but be aware that the total course of treatment must be discontinued after 3 months.
4. A reassessment must be performed after 4 weeks; if the medicine has not produced a response by this point, it must be stopped and an alternative treatment must be sought.

This structure defines the precise oral administration, the daily frequency, the absolute maximum duration of therapy, and a mandatory checkpoint for efficacy, while also clearly excluding patients over 60 years of age and children from receiving this medicine.

Research Evidence / Overview of Studies for Motival

This section provides an overview of the research studies conducted on the fixed-dose combination of Nortriptyline and Fluphenazine (Motival), summarizing the types of evidence that exist, what was studied, and what remains uncertain. This information is drawn from regulatory and peer-reviewed scientific sources.

---

Evidence for Use in Mixed Anxiety and Depressive States

Research explored the combination's use in individuals reporting overlapping symptoms of mood disturbance and tension, particularly those presenting in out-patient settings. Studies exploring this indication primarily utilized short-term Randomized Controlled Trials (RCTs) and comparative clinical studies. These trials examined how symptoms changed over defined time intervals.

Researchers studied outcomes related to both mood and tension. Findings describe patterns observed in the studies; research reports how symptoms evolved in the observed populations over the study period. However, the evidence is subject to certain limitations. Many of the key comparative studies were conducted decades ago, meaning they used diagnostic criteria that may differ from those used today. Furthermore, the follow-up durations were limited, typically lasting only about four weeks. This research provides context regarding short-term changes but does not determine whether an individual will respond similarly or how studies monitored its effects over a longer duration.

---

Evidence for Use in Chronic Psychoses (Supportive Management)

Research has also explored the combination's use in individuals with chronic psychoses who have concurrent symptoms of depression. The research here relies more on the existing research findings for the Fluphenazine component (an antipsychotic) and clinical observations, with fewer large, combination-specific RCTs available.

Studies examined outcomes related to how symptoms changed, including the measurement of psychotic features, and also monitored outcomes reflecting daily functioning or activity level. The certainty remains low regarding the specific long-term role of the fixed-dose combination in this patient group. Limited information is available for long-term outcomes of the combination itself, and comparative evidence is lacking when weighing the fixed-dose combination against the two components being prescribed separately.

---

What is Still Uncertain About Motival's Research

There are several areas where the research evidence remains limited or uncertain. The evidence quality varies across studies, and many key trials were conducted before modern, rigorous trial standards and current diagnostic classifications were widely adopted. Sample sizes were modest in some of the original trials, and comparative evidence is lacking for certain modern treatment standards. The data show patterns related to short-term symptom changes, but the long-term effects are not fully established. This research provides context but not individual predictions about long-term success.

Key Studies & References

1. Fluphenazine Hydrochloride Tablets, USP (DailyMed - Regulatory Labeling for component drug)

Common questions about Motival (FAQ)

Q: What is Motival used for?

Motival is a medication that combines two active ingredients: nortriptyline and fluphenazine. It is primarily prescribed to treat symptoms associated with certain types of depression and anxiety where both emotional and physical symptoms are present.

Q: How does Motival work?

Motival works through the combined actions of its two components:

• Nortriptyline is a tricyclic antidepressant (TCA). It works by increasing the levels of certain natural substances, like norepinephrine and serotonin, in the brain. These chemicals help regulate mood and nerve function, which can improve symptoms of depression.
• Fluphenazine is a phenothiazine antipsychotic. It works by blocking the action of dopamine in the brain. This can help to reduce severe anxiety, tension, and agitation often associated with depression.

Q: Is Motival a controlled substance?

No, Motival is not typically classified as a controlled substance in the United States or the United Kingdom. However, it is a prescription-only medication in most countries due to the potential for serious side effects and the need for close medical supervision.

Q: What are common side effects of Motival?

Because Motival contains two active drugs, it has a range of potential side effects. Common side effects may include:

• Dry mouth
• Drowsiness or dizziness
• Blurred vision
• Constipation
• Difficulty urinating
• Changes in appetite or weight
• Orthostatic hypotension (a drop in blood pressure when standing up)
• Tremor or muscle stiffness

If any side effect becomes severe or persistent, a healthcare provider should be contacted.

Q: Can I stop taking Motival suddenly?

No, you should never stop taking Motival suddenly without talking to your healthcare provider first. Stopping abruptly can lead to withdrawal symptoms or a return of your original symptoms.

Your healthcare provider will guide you through a process called tapering, which involves gradually reducing the dose over a period of time. This is done to help your body adjust and minimize the risk of adverse effects.

Q: Can Motival be taken with alcohol?

No, consuming alcohol while taking Motival is strongly discouraged. Both alcohol and Motival can cause drowsiness and dizziness. Combining them significantly increases this sedative effect, which can impair judgment, coordination, and the ability to operate machinery safely.

Mixing Motival and alcohol may also increase the risk of other side effects and may affect the medication's effectiveness.

How to Store and Dispose of Motival (Nortriptyline and Fluphenazine)

The storage and disposal of Motival Tablets must strictly follow regulatory guidance to maintain stability and ensure safety. This prescription medication requires specific environmental controls:

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C). Do not freeze.
Protection	Protect from light and moisture. Keep in a cool, dry place and in the original container, tightly closed.
Safety	Keep out of the sight and reach of children and pets in a secure location.

Disposal Instructions

Official disposal is primarily through a drug take-back program or pharmaceutical waste collection. If a take-back program is unavailable, expired or unused tablets should be made undesirable (e.g., mixed with dirt, not crushed) and sealed in a container before being placed in household trash. Do not flush Motival down the toilet or pour it down a sink.